These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 3250915)

  • 21. The broad-spectrum anti-emetic activity of AS-8112, a novel dopamine D2, D3 and 5-HT3 receptors antagonist.
    Yoshikawa T; Yoshida N; Oka M
    Br J Pharmacol; 2001 May; 133(2):253-60. PubMed ID: 11350861
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Experimental catalepsy is both enhanced and disrupted by apomorphine.
    Klemm WR
    Psychopharmacology (Berl); 1985; 87(1):12-5. PubMed ID: 3933030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety profile assessment of buflomedil: an overview of adverse reactions between 1975 and 2011.
    Bucolo C; Longo L; Camillieri G; Drago F; Salomone S
    Pharmacoepidemiol Drug Saf; 2012 Nov; 21(11):1190-6. PubMed ID: 22855302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quinpirole, 8-OH-DPAT and ketanserin modulate catalepsy induced by high doses of atypical antipsychotics.
    Ninan I; Kulkarni SK
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):603-8. PubMed ID: 10669905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The neurosteroid 3 alpha-hydroxy-5 alpha-pregnan-20-one induces catalepsy in mice.
    Khisti RT; Mandhane SN; Chopde CT
    Neurosci Lett; 1998 Jul; 251(2):85-8. PubMed ID: 9718980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Mechanism of emetic action of adrenaline and histamine in the dog].
    Legeza VI; Shagoian MG; Kamynina MF
    Farmakol Toksikol; 1984; 47(3):41-3. PubMed ID: 6734805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Caffeine and muscarinic antagonists act in synergy to inhibit haloperidol-induced catalepsy.
    Moo-Puc RE; Góngora-Alfaro JL; Alvarez-Cervera FJ; Pineda JC; Arankowsky-Sandoval G; Heredia-López F
    Neuropharmacology; 2003 Sep; 45(4):493-503. PubMed ID: 12907310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potentiation of domperidone-induced catalepsy by a P-glycoprotein inhibitor, cyclosporin A.
    Tsujikawa K; Dan Y; Nogawa K; Sato H; Yamada Y; Murakami H; Ohtani H; Sawada Y; Iga T
    Biopharm Drug Dispos; 2003 Apr; 24(3):105-14. PubMed ID: 12673668
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 3-O-methyldopa attenuates the effects of Madopar on the haloperidol-induced cataleptic behavior and the locomotor activity in the mouse.
    Himori N; Tanaka Y; Kurasawa M; Mishima K; Akaike N
    Pharmacology; 1994 Apr; 48(4):226-33. PubMed ID: 8177909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Catalepsy induced by SCH 23390 in rats.
    Morelli M; Di Chiara G
    Eur J Pharmacol; 1985 Nov; 117(2):179-85. PubMed ID: 2866970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties.
    Bardin L; Kleven MS; Barret-Grévoz C; Depoortère R; Newman-Tancredi A
    Neuropsychopharmacology; 2006 Sep; 31(9):1869-79. PubMed ID: 16237379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of cardiorenal and emetic effects of dopamine prodrugs docarpamine (TA-870) and levodopa in dogs.
    Nishiyama S; Kanno K; Yamaguchi I
    J Pharmacobiodyn; 1991 Mar; 14(3):120-5. PubMed ID: 1679131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Haloperidol-induced catalepsy is influenced by calcium channel antagonists.
    Biała G
    Acta Pol Pharm; 2000; 57(3):233-7. PubMed ID: 11143713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FK506 as effective adjunct to L-dopa in reserpine-induced catalepsy in rats.
    Singh A; Naidu PS; Kulkarni SK
    Indian J Exp Biol; 2003 Nov; 41(11):1264-8. PubMed ID: 15332494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of dopamine in the formation of gastric ulcers in rats.
    Sikirić P; Geber J; Suchanek E; Ivanović D; Gjuris V; Aleksić J; Reić P; Marović A
    Eur J Pharmacol; 1985 May; 112(1):127-8. PubMed ID: 4018137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular actions of buflomedil and possible mechanisms involved.
    Kushiku K; Ohba M; Mikagi T; Nuki S; Araki Y; Furukawa T
    Arzneimittelforschung; 1989 Jun; 39(6):670-7. PubMed ID: 2775333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice.
    Gomes FV; Del Bel EA; Guimarães FS
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():43-7. PubMed ID: 23791616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of buflomedil on isolated dog arteries.
    Toda N; Okunishi H; Okamura T; Miyazaki M
    Arch Int Pharmacodyn Ther; 1983 Nov; 266(1):117-30. PubMed ID: 6667061
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mirtazapine enhances the effect of haloperidol on apomorphine-induced climbing behaviour in mice and attenuates haloperidol-induced catalepsy in rats.
    Berendsen HH; Broekkamp CL; Pinder RM
    Psychopharmacology (Berl); 1998 Feb; 135(3):284-9. PubMed ID: 9498732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolerance of haloperidol catalepsy.
    Ezrin-Waters C; Seeman P
    Eur J Pharmacol; 1977 Feb; 41(3):321-7. PubMed ID: 556989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.